Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 Combination Therapy in Advanced Esophageal Squamous Cell Carcinoma
NCT07484724Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of JS212 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2026; status: recruiting.
02
Drugs
JS212
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07484724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484724.